Brian C. Miller
YOU?
Author Swipe
View article: 799 Dissecting the role of folate receptor beta-mediated one-carbon metabolism in tumor-associated macrophages
799 Dissecting the role of folate receptor beta-mediated one-carbon metabolism in tumor-associated macrophages Open
View article: Intra-tumoral hypoxia promotes CD8+ T cell dysfunction via chronic activation of integrated stress response transcription factor ATF4
Intra-tumoral hypoxia promotes CD8+ T cell dysfunction via chronic activation of integrated stress response transcription factor ATF4 Open
Metabolic stress in the tumor microenvironment (TME) promotes T cell dysfunction and immune checkpoint inhibitor (ICI) resistance. We examined the contribution of activating transcription factor 4 (ATF4), the central node of the integrated…
View article: Single-cell transcriptomics yield insights into the stress-immune interplay and inform disease risk
Single-cell transcriptomics yield insights into the stress-immune interplay and inform disease risk Open
Environmental stress contributes to several disease conditions – including cardiovascular disease, mental illness, and autoimmune disorders – through immune dysregulation. Stress operates through the hypothalamic-pituitary-adrenal and symp…
View article: Epigenetic tuning of PD-1 expression improves exhausted T cell function and viral control
Epigenetic tuning of PD-1 expression improves exhausted T cell function and viral control Open
PD-1 is a key negative regulator of CD8+ T cell activation and is highly expressed by exhausted T cells in cancer and chronic viral infection. Although PD-1 blockade can improve viral and tumor control, physiological PD-1 expression preven…
View article: Comparison of Intraoperative Fentanyl Usage and Waste After Transition from 100-μg Vials to 50-μg Preloaded Syringes: A Single-Center Retrospective Study
Comparison of Intraoperative Fentanyl Usage and Waste After Transition from 100-μg Vials to 50-μg Preloaded Syringes: A Single-Center Retrospective Study Open
Background: The rapidly acting opioid fentanyl, commonly used in the perioperative setting, has traditionally been packaged in 100 or 250-μg vials. In September 2021, our institution implemented a change from fentanyl 100-μg vials to 50-μg…
View article: Figure S2 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
Figure S2 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity Open
Supplemental Figure 2
View article: Figure S7 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
Figure S7 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity Open
Supplemental Figure 7
View article: Figure S4 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
Figure S4 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity Open
Supplemental Figure 4
View article: Data from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
Data from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity Open
Progressive decline of the adaptive immune system with increasing age coincides with a sharp increase in cancer incidence. In this study, we set out to understand whether deficits in antitumor immunity with advanced age promote tumor progr…
View article: Figure S5 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
Figure S5 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity Open
Supplemental Figure 5
View article: Figure S6 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
Figure S6 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity Open
Supplemental Figure 6
View article: Figure S1 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
Figure S1 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity Open
Supplemental Figure 1
View article: Figure S8 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
Figure S8 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity Open
Supplemental Figure 8
View article: Figure S3 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
Figure S3 from Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity Open
Supplemental Figure 3
View article: Supplementary Tables 1 from Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201)
Supplementary Tables 1 from Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201) Open
Supplementary Tables
View article: Supplementary Figure 1 from Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201)
Supplementary Figure 1 from Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201) Open
Supplementary Figure 1
View article: Data from Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201)
Data from Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201) Open
Purpose:Mutations in hematopoietic progenitor cells accumulate with age leading to clonal expansion, termed clonal hematopoiesis (CH). CH in the general population is associated with hematopoietic neoplasms and reduced overall survival (OS…
View article: Supplementary Data 1 from Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201)
Supplementary Data 1 from Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201) Open
Supplementary Data
View article: 914 The tumor microenvironment enforces ATF4 in CD8<sup>+</sup> TILs to obstruct immune checkpoint blockade efficacy
914 The tumor microenvironment enforces ATF4 in CD8<sup>+</sup> TILs to obstruct immune checkpoint blockade efficacy Open
View article: 1465 Denosumab improves clinical benefit of PD1 inhibitors in metastatic melanoma (MM) presumably via a suppressive effect on immunoregulatory myeloid cell populations
1465 Denosumab improves clinical benefit of PD1 inhibitors in metastatic melanoma (MM) presumably via a suppressive effect on immunoregulatory myeloid cell populations Open
View article: Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201)
Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201) Open
Purpose: Mutations in hematopoietic progenitor cells accumulate with age leading to clonal expansion, termed clonal hematopoiesis (CH). CH in the general population is associated with hematopoietic neoplasms and reduced overall survival (O…
View article: Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity
Age-Associated Contraction of Tumor-Specific T Cells Impairs Antitumor Immunity Open
Progressive decline of the adaptive immune system with increasing age coincides with a sharp increase in cancer incidence. In this study, we set out to understand whether deficits in antitumor immunity with advanced age promote tumor progr…
View article: A synthetic lethal screen for Snail-induced enzalutamide resistance identifies JAK/STAT signaling as a therapeutic vulnerability in prostate cancer
A synthetic lethal screen for Snail-induced enzalutamide resistance identifies JAK/STAT signaling as a therapeutic vulnerability in prostate cancer Open
Despite substantial improvements in the treatment landscape of prostate cancer, the evolution of hormone therapy-resistant and metastatic prostate cancer remains a major cause of cancer-related death globally. The mainstay of treatment for…
View article: A synthetic lethal screen for Snail-induced enzalutamide resistance identifies JAK/STAT signaling as a therapeutic vulnerability in prostate cancer
A synthetic lethal screen for Snail-induced enzalutamide resistance identifies JAK/STAT signaling as a therapeutic vulnerability in prostate cancer Open
Despite substantial improvements in the treatment landscape of prostate cancer, the evolution of hormone therapy-resistant and metastatic prostate cancer remains a major cause of cancer-related death globally. The mainstay of treatment for…
View article: Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition Open
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
View article: Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition Open
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
View article: Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition Open
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
View article: Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition Open
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
View article: Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition Open
Supplementary Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
View article: Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition
Data from Microenvironmental Landscape of Human Melanoma Brain Metastases in Response to Immune Checkpoint Inhibition Open
Melanoma-derived brain metastases (MBM) represent an unmet clinical need because central nervous system progression is frequently an end stage of the disease. Immune checkpoint inhibitors (ICI) provide a clinical opportunity against MBM; h…